I am a Principal Scientist and Biomarker Expert at Roche, focused on developing and implementing biomarker strategies for clinical trials in neurodevelopmental disorders and neurodegenration. With a PhD in sleep-wake regulation and a background in biomedical engineering, my core expertise lies in neurophysiology, EEG, and the statistical processing of complex clinical data. Within the Angelman syndrome space, I have worked on and analyzed objective biomarkers, including polysomnography and sleep mat data, from the FREESIAS observational study and the TANGELO interventional trial.